Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals.
about
Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone.Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection.Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment.Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects.
P2860
Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effects of HCV seropositive st ...... opioid-dependent individuals.
@en
Effects of HCV seropositive st ...... opioid-dependent individuals.
@nl
type
label
Effects of HCV seropositive st ...... opioid-dependent individuals.
@en
Effects of HCV seropositive st ...... opioid-dependent individuals.
@nl
prefLabel
Effects of HCV seropositive st ...... opioid-dependent individuals.
@en
Effects of HCV seropositive st ...... opioid-dependent individuals.
@nl
P2093
P2860
P1476
Effects of HCV seropositive st ...... opioid-dependent individuals.
@en
P2093
Carmen L Masson
David E Moody
Elinore F McCance-Katz
Petrie M Rainey
P2860
P356
10.1111/J.1521-0391.2013.12052.X
P577
2013-06-10T00:00:00Z